NDAINHALATIONAEROSOL, METERED
Approved
Apr 2023
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBICORT AEROSPHERE is a metered-dose inhaler combining budesonide (inhaled corticosteroid) and formoterol (long-acting beta-2 agonist) approved in April 2023. It treats asthma and COPD by reducing airway inflammation and bronchospasm. The AeroSphere technology delivers improved particle size distribution for enhanced lung deposition.
Peak3.7 years to LOE
Recently approved product in peak growth phase; commercial teams are actively scaling market presence with potential for significant headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on SYMBICORT AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.